|
September 26, 2024
|
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
|
|
September 3, 2024
|
Enanta Pharmaceuticals to Participate in Investor Conferences in September
|
|
August 5, 2024
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
|
|
May 29, 2024
|
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
|
|
May 7, 2024
|
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
|
|
May 6, 2024
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
|
|
April 30, 2024
|
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
April 30, 2024
|
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
|
|
April 29, 2024
|
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
|
|
April 17, 2024
|
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
|